Sorry for the Run-on sentences in advance. If you have any questions about my research or any data related to my blogs, just inquire about them via comment.
I am a 20 year old finance student studying the pharmaceutical industry and in particular the top performing industries of Biotech and life science research. I research companies that target untapped markets and follow capital expenditure trends of the industry to capitalize on surrounding opportunities. Companies working with government funded research institutions (NIH, Foundations, Universities) are my favorite long picks. I am long small caps with strong pipelines and balance sheets, and short most one trick unicorns that don't have value or technical support. I pick my trades on a company by company basis. I don't always require that a company is involved in a favorable industry that has unmet demand by big pharma, but that is where I believe discrepancies in valuations occur most often. Recently, I have moved with momentum and enjoy testing hype in valuations.
I use fundamental analysis, some historical pricing model techniques, and ultimately, macro themes to build and test my thesis's for industry analysis and trading. I always trade on technical analysis, but find value in fundamentals.
In 2016, my Biotech industry top picks are involved in the clinical development of therapies in ophthalmology (Dry eye, DME, AMD), rare diseases (MF, Lupus, DMD), lung disorders (COPD), cardiovascular diseases (PAH, DCM, CLI), and breakthrough cancer therapies (so basically anything Celgene, Roche, and Novartis miss).
Expecting a lot of crowding in Melanoma (ex. RXDX, ARRY) and cholesterol drugs (ex. $ESPR, $AEGR) in 2016 with multiple expected drug launches. Finally, I am excited for Biosimilars to make their debut in 2016. Many patent expirations in 2017 and before 2019 should open up some serious patent cases. I am still expecting a ton of BLAs to be filed in 2016 (ex. $PFNX, $EPRS, $MNTA, $SRNE).
Thanks for reading, tweet @Kuritzmike if you want to see what I'm trading on the day to day.
Recently retired from mainframe & Internet It career, I am still an active investor focusing on mobile tech and renewable energy tech, with funds for less well understood promising technologies and safe income.